Zögg Thomas, Brandstetter Hans
Department of Molecular Biology, Division of Structural Biology, University of Salzburg, Billrothstrasse 11, A-5020 Salzburg, Austria.
Biol Chem. 2009 May-Jun;390(5-6):391-400. doi: 10.1515/BC.2009.057.
Blood haemostasis is accomplished by a complex network of coagulatory and fibrinolytic processes. These processes have to be delicately balanced, as clinically manifested by bleeding disorders, such as haemophilia A and B. These disorders are caused by defects in coagulation factor VIII and factor IX, respectively. Following a dual strategy, we emphasise on the one hand principles conserved in most coagulation enzymes, thus mirroring much of the underlying complexity in haemostasis; on the other hand, we identify enzymatic properties of the factor IXa-factor VIIIa system (Xase) that distinguish this proteolytic machine from other components of the coagulation system. While the exact mechanisms of its activity modulation remain baffling until today, superactive factor IX mutants significantly improve our current understanding and serve as a specific and testable model of Xase action.
血液止血是通过一个由凝血和纤维蛋白溶解过程组成的复杂网络来完成的。这些过程必须精确平衡,如血友病A和B等出血性疾病所临床表现的那样。这些疾病分别由凝血因子VIII和因子IX的缺陷引起。遵循双重策略,一方面,我们强调大多数凝血酶中保守的原理,从而反映出血液止血中许多潜在的复杂性;另一方面,我们确定因子IXa-因子VIIIa系统(Xase)的酶学特性,该特性将这种蛋白水解机制与凝血系统的其他成分区分开来。虽然其活性调节的确切机制至今仍令人困惑,但超活性因子IX突变体显著提高了我们目前的理解,并作为Xase作用的一个特定且可测试的模型。